患者性别与化疗相关毒性效应的关联：EORTC 胃肠道肿瘤研究组开展的 PETACC-3 试验的回顾性分析。
Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group.
机构信息
Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Statistics Department, EORTC Headquarters, Brussels, Belgium.
出版信息
JAMA Oncol. 2018 Jul 1;4(7):1003-1006. doi: 10.1001/jamaoncol.2018.1080.
Abstract
This secondary analysis of the PETACC-3 trial examines the association of sex with incidence and severity of chemotherapy-related toxic effects in patients with stage II and III colorectal cancer treated with fluorouracil and leucovorin with or without irinotecan hydrochloride.
摘要
本研究为 PETACC-3 试验的二次分析，旨在探讨氟尿嘧啶和亚叶酸联合或不联合盐酸伊立替康治疗 II 期和 III 期结直肠癌患者的化疗相关毒副反应发生率和严重程度与性别之间的相关性。
相似文献
1
Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group.患者性别与化疗相关毒性效应的关联：EORTC 胃肠道肿瘤研究组开展的 PETACC-3 试验的回顾性分析。
JAMA Oncol. 2018 Jul 1;4(7):1003-1006. doi: 10.1001/jamaoncol.2018.1080.
2
From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors.从传统化疗到靶向治疗：单克隆抗体在胃肠道肿瘤中的应用
Tumour Biol. 2014 Sep;35(9):8471-82. doi: 10.1007/s13277-014-2367-1. Epub 2014 Jul 26.
3
Preventing adverse events of chemotherapy by educating patients about the nocebo effect (RENNO study) - study protocol of a randomized controlled trial with gastrointestinal cancer patients.通过向患者教育关于反安慰剂效应来预防化疗不良事件（RENNO 研究）-一项针对胃肠道癌患者的随机对照试验研究方案。
BMC Cancer. 2018 Sep 24;18(1):916. doi: 10.1186/s12885-018-4814-7.
4
[Safe drug treatment. More communication, enhanced security].[安全药物治疗。更多沟通，增强安全性]
Med Monatsschr Pharm. 2014 Jul;37(7):265.
5
[Randomized controlled clinical trial of kang'ai injection in gastrointestinal cancerchemotherapy patients].康艾注射液用于胃肠道癌化疗患者的随机对照临床试验
Zhongguo Zhong Yao Za Zhi. 2012 Oct;37(19):2990-2.
6
Low rates of symptomatic venous thromboembolism in patients with gastrointestinal cancer: an Iranian study.胃肠道癌患者有症状静脉血栓栓塞的低发生率：一项伊朗的研究。
Blood Coagul Fibrinolysis. 2017 Jul;28(5):351-355. doi: 10.1097/MBC.0000000000000601.
7
Cancer survivorship: long-term side-effects of anticancer treatments of gastrointestinal cancer.癌症幸存者：胃肠道癌抗癌治疗的长期副作用
Curr Opin Oncol. 2015 Jul;27(4):351-7. doi: 10.1097/CCO.0000000000000203.
8
Oral administration of the amino acids cystine and theanine attenuates the adverse events of S-1 adjuvant chemotherapy in gastrointestinal cancer patients.口服氨基酸胱氨酸和茶氨酸可减轻胃肠道癌症患者S-1辅助化疗的不良事件。
Int J Clin Oncol. 2016 Dec;21(6):1085-1090. doi: 10.1007/s10147-016-0996-7. Epub 2016 Jun 15.
9
Gastric pneumatosis: an unexpected complication of intractable vomiting in gastrointestinal cancers.胃壁积气：胃肠癌顽固性呕吐的意外并发症。
J Pain Symptom Manage. 2015 Apr;49(4):e3-4. doi: 10.1016/j.jpainsymman.2014.12.006. Epub 2015 Jan 24.
10
Effect of Fuzheng Yiliu decoction combined with chemotherapy on patients with intermediate and late stage gastrointestinal cancer.扶正抑瘤汤联合化疗对中晚期胃肠道癌患者的影响。
World J Gastroenterol. 2005 Jan 21;11(3):439-42. doi: 10.3748/wjg.v11.i3.439.
引用本文的文献
1
Diversity and inclusivity in oncology: A narrative review and orientation for institutional measures in Germany.肿瘤学中的多样性与包容性：德国机构措施的叙述性综述与指南
Transl Oncol. 2025 Oct;60:102493. doi: 10.1016/j.tranon.2025.102493. Epub 2025 Aug 8.
2
Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial.年龄和性别对雷莫西尤单抗联合紫杉醇作为一线奥沙利铂化疗的转换维持治疗与继续治疗的疗效和安全性的影响：ARMANI III期试验的亚组分析
ESMO Open. 2025 Jun 19;10(7):105329. doi: 10.1016/j.esmoop.2025.105329.
3
Gut-derived from exceptional responders mitigates chemoradiotherapy-induced intestinal injury through methionine-driven epigenetic modulation.来自超反应者的肠道源物质通过蛋氨酸驱动的表观遗传调控减轻放化疗引起的肠道损伤。
Imeta. 2025 May 14;4(3):e70043. doi: 10.1002/imt2.70043. eCollection 2025 Jun.
4
Gender impact on safety and efficacy in lenvatinib treated patients with radioiodine-refractory differentiated thyroid cancer (GISEL study).性别对乐伐替尼治疗的放射性碘难治性分化型甲状腺癌患者安全性和疗效的影响（GISEL研究）
Eur Thyroid J. 2025 Apr 23;14(2). doi: 10.1530/ETJ-24-0386. Print 2025 Apr 1.
5
Sex differences in the pharmacokinetics of anticancer drugs: a systematic review.抗癌药物药代动力学中的性别差异：一项系统评价。
ESMO Open. 2024 Dec;9(12):104002. doi: 10.1016/j.esmoop.2024.104002. Epub 2024 Dec 10.
6
[Sex differences in pancreatic cancer].[胰腺癌中的性别差异]
Chirurgie (Heidelb). 2024 Sep;95(9):709-714. doi: 10.1007/s00104-024-02150-6. Epub 2024 Aug 15.
7
Impact of Patient Sex on Adverse Events and Unscheduled Utilization of Medical Services in Cancer Patients Undergoing Adjuvant Chemotherapy: A Multicenter Retrospective Cohort Study.患者性别对接受辅助化疗的癌症患者不良事件和非计划性医疗服务利用的影响：一项多中心回顾性队列研究。
Cancer Res Treat. 2024 Apr;56(2):404-413. doi: 10.4143/crt.2023.784. Epub 2023 Nov 7.
8
[Sex-specific differences of special tumor diseases].[特殊肿瘤疾病的性别差异]
Inn Med (Heidelb). 2023 Aug;64(8):717-726. doi: 10.1007/s00108-023-01551-9. Epub 2023 Jul 17.
9
Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212).帕尼单抗联合氟尿嘧啶和亚叶酸治疗与单用氟尿嘧啶和亚叶酸维持治疗对 RAS WT 转移性结直肠癌（mCRC）患者疗效和安全性的影响：PanaMa 研究（AIO-KRK-0212）的亚组分析。
ESMO Open. 2023 Aug;8(4):101568. doi: 10.1016/j.esmoop.2023.101568. Epub 2023 Jul 11.
10
Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A Perspective.通过即时治疗药物监测和传统细胞毒性化疗药物剂量调整实现精准肿瘤学：一种观点
Pharmaceutics. 2023 Apr 19;15(4):1283. doi: 10.3390/pharmaceutics15041283.
本文引用的文献
1
Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients.男性和女性癌症患者分子差异的综合表征
Cancer Cell. 2016 May 9;29(5):711-722. doi: 10.1016/j.ccell.2016.04.001.
2
An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients.用于预测晚期结直肠癌患者伊立替康诱导的严重中性粒细胞减少风险的内部和外部验证的列线图。
Br J Cancer. 2015 May 12;112(10):1709-16. doi: 10.1038/bjc.2015.122. Epub 2015 Apr 16.
3
Part 1: background, methodology, and clinical adoption of pharmacogenetics.第一部分：遗传药理学的背景、方法学和临床应用。
Oncologist. 2011;16(6):811-9. doi: 10.1634/theoncologist.2010-0258. Epub 2011 May 31.
4
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.比较每两周输注氟尿嘧啶/亚叶酸钙单药或联合伊立替康辅助治疗Ⅲ期结肠癌的随机Ⅲ期试验：PETACC-3
J Clin Oncol. 2009 Jul 1;27(19):3117-25. doi: 10.1200/JCO.2008.21.6663. Epub 2009 May 18.
5
Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals.美国白种人和亚洲人群中UGT1A1*28多态性的分布：138名健康个体的基因组分析。
Anticancer Drugs. 2007 Jul;18(6):693-6. doi: 10.1097/CAD.0b013e32803a46fe.
6
Sex differences in pharmacokinetics and pharmacodynamics.药代动力学和药效学中的性别差异。
Annu Rev Pharmacol Toxicol. 2004;44:499-523. doi: 10.1146/annurev.pharmtox.44.101802.121453.
Zotero 插件